Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide BPC 157, prophylaxis and therapy.
We focused on abdominal aorta, clamped and transected bellow renal arteries, and aortic termino-terminal anastomosis created in Albino male rats. We suggested stomach cytoprotection theory holding endothelium protection and peptidergic anti-ulcer cytoprotection therapy to improve management of abdominal aorta anastomosis and thrombus formation. The stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419) is a small anti-ulcer peptide efficient in inflammatory bowel disease trials (PL 14736) and various wound treatment, no toxicity reported. After 24 h following aortic termino-terminal anastomosis, we shown that BPC 157 (10 microg/kg) may also decrease formation of cloth after aortic termino-terminal anastomosis and preserved walking ability and muscle strength when given as a bath immediately after aortic anastomosis creation. This may be important since aortic termino-terminal anastomosis is normally presenting in rats with a formed cloth obstructing more than third of aortic lumen, severely impaired walking ability, painful screaming and weak muscle strength. Thereby, the effect of BPC 157 (10 microg/kg) was additionally studied at 24 h following aortic termino-terminal anastomosis. Given at the that point, intraperitoneally, within 3 minutes post-application interval the pentadecapeptide BPC 157 rapidly recovered the function of lower limbs and muscle strength while no cloth could be seen in those rats at the anastomosis site.
Hrelec
M
M
Department of Pharmacology and Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia.
Klicek
R
R
Brcic
L
L
Brcic
I
I
Cvjetko
I
I
Seiwerth
S
S
Sikiric
P
P
D000714:Anastomosis, Surgical / Q000534:rehabilitation*; D000818:Animals; D001012:Aorta, Abdominal / Q000473:pathology / Q000601:surgery*; D004333:Drug Administration Routes; D004730:Endothelium, Vascular / Q000293:injuries; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006614:Hindlimb; D007430:Intraoperative Care / Q000379:methods; D008297:Male; D053580:Muscle Strength / Q000187:drug effects; D010149:Postoperative Pain / Q000188:drug therapy; D010291:Paresis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D011506:Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012720:Severity of Illness Index; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D013997:Time Factors; D014652:Vascular Diseases / Q000188:drug therapy; D016138:Walking
D005343:Fibrinolytic Agents; D010446:Peptide Fragments; D011506:Proteins; C083833:BPC 157